<DOC>
	<DOCNO>NCT00753272</DOCNO>
	<brief_summary>The purpose study evaluate efficacy GlaxoSmithKline Biologicals ' influenza vaccine GSK2186877A adult 65 year age older . The study design divide two surveillance phase : one passive phase along study influenza season one active surveillance phase influenza peak season .</brief_summary>
	<brief_title>Trial Evaluate Efficacy GSK Biologicals ' Influenza Vaccine GSK2186877A Adults 65 Year Age Older</brief_title>
	<detailed_description>This Protocol Posting update accord Protocol Amendment 3 , Sep 2009 . After analysis study complete , question arise regard integrity study data single study site Romania , enrol 102 subject trial . Because evaluation data site reveal irregularity compare overall study data GSK current plan use data study support regulatory filing , exclude analysis reflect result summary .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A man woman age 65 year old time vaccination . Written inform consent obtain subject . Subjects residence status allow free mix general community . Bedridden subject Previous vaccination influenza since February 2008 . Previous vaccination last three year investigational adjuvanted candidate seasonal pandemic influenza vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Any contraindication intramuscular administration influenza vaccine . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine include egg chicken protein . Acute disease time enrolment . Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e . Oral temperature &lt; 37.5°C ( 99.5°F ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Influenza Vaccines</keyword>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Elderly</keyword>
</DOC>